Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | BACE1 | P56817 | 1/20 | 0.44 |
| ▸ | NSD2 | O96028 | 2/20 | 0.43 |
| ▸ | IRAK4 | Q9NWZ3 | 3/20 | 0.43 |
| ▸ | TNF | P01375 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 3/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.42 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.41 |
| ▸ | DNMT3A | Q9Y6K1 | 1/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7566263 | 1.00 | GPR119 (0.44) | GPR119ACHEBACE1NSD2IRAK4 | |
| SCHEMBL7566257 | 1.00 | GPR119 (0.44) | GPR119ACHEBACE1NSD2IRAK4 | |
| SCHEMBL7566293 | 0.95 | ACHE (0.41) | GPR119ACHEBACE1IRAK4TNF | |
| SCHEMBL7564323 | 0.95 | GPR119 (0.49) | GPR119ACHEBACE1NSD2IRAK4 | |
| SCHEMBL7565400 | 0.94 | ACHE (0.45) | ACHEBACE1IRAK4TNFPDE4B | |
| SCHEMBL7598322 | 0.94 | ACHE (0.45) | ACHEBACE1IRAK4TNFPDE4B | |
| SCHEMBL7565390 | 0.94 | ACHE (0.45) | ACHEBACE1IRAK4TNFPDE4B | |
| SCHEMBL7564215 | 0.90 | ACHE (0.45) | ACHEBACE1NSD2IRAK4 | |
| SCHEMBL7566674 | 0.90 | ACHE (0.45) | ACHEBACE1NSD2IRAK4 | |
| SCHEMBL7565173 | 0.90 | ACHE (0.45) | ACHEBACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020193614-A1 | Anthranilic acid derivatives as inhibitors of the CGMP-phosphodiesterase | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2002-12-19 | — | — | US | disclosed |
| US-6384080-B1 | TREATMENT AND/OR PREVENTION OF CERTAIN CARDIOVASCULAR DISORDERS, UROGENITAL DISORDERS, RESPIRATORY SYSTEM DISORDERS, DISORDERS OF GUT MOTILITY, SEXUAL DISORDERS, DIABETIC COMPLICATIONS, URTICARIA | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193614-A1 | Anthranilic acid derivatives as inhibitors of the CGMP-phosphodiesterase | PDE3A, PDE2A, PDE5A | GPR119 1465/4885ACHE 185/4885BACE1 2396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.